Laurent Gorin1, Laurent Fauchier2, Emilie Nonin1, Bernard Charbonnier3, Dominique Babuty3, Gregory Y H Lip4. 1. Service de Cardiologie, Centre Hospitalier Universitaire Trousseau, Tours, France; Hôpital Cardiologique Louis Pradel, Bron, France. 2. Service de Cardiologie, Centre Hospitalier Universitaire Trousseau, Tours, France; Faculté de Médecine, Université François Rabelais, Tours, France. Electronic address: lfau@med.univ-tours.fr. 3. Service de Cardiologie, Centre Hospitalier Universitaire Trousseau, Tours, France; Faculté de Médecine, Université François Rabelais, Tours, France. 4. University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, England.
Abstract
BACKGROUND: In patients with atrial fibrillation (AF), adherence to guidelines for antithrombotic treatment is poorly followed, and undertreatment (or nonadherence with guidelines) is associated with a worse prognosis. The study objective was to evaluate whether this was also the case in a large contemporary series of unselected patients with AF in real-world clinical practice. METHODS: All patients with AF or atrial flutter seen in our institution between 2000 and 2007 were identified in a database and followed up for mortality and stroke. Antithrombotic guideline adherence was assessed according to the 2006 American College of Cardiology/American Heart Association/European Society of Cardiology guidelines. RESULTS: We reviewed outcomes in 3,646 consecutive patients with AF or atrial flutter (aged 71 ± 14 years; mean CHADS(2) [congestive heart failure, hypertension, aged ≥ 75 years, diabetes mellitus, prior stroke or transient ischemic attack] score, 1.5 ± 1.1). Antithrombotic treatment was in agreement with the guidelines in 53% of patients, whereas 31% were classified as undertreated and 16% as overtreated. Among other parameters, nonpermanent AF and atrial flutter were independently associated with an increased risk of undertreatment. After a follow-up of 953 ± 767 days (median, 771 days; interquartile range, 1,286 days), guideline adherence was associated with a lower risk of adverse events (death from all causes or stroke) compared with undertreatment (relative risk, 0.47; 95% CI, 0.40-0.55; P < .0001). Overtreatment was associated with a lower risk of adverse events compared with the guideline-adherent population (relative risk, 0.40; 95% CI, 0.28-0.58; P < .0001). Factors independently associated with increased risk of mortality or stroke were antithrombotic undertreatment, older age, heart failure, renal failure, diabetes, male sex, and previous history of stroke. CONCLUSIONS: Guideline nonadherence and undertreatment with antithrombotic agents in unselected real-world patients with AF or atrial flutter are independently associated with a high risk of stroke and mortality.
BACKGROUND: In patients with atrial fibrillation (AF), adherence to guidelines for antithrombotic treatment is poorly followed, and undertreatment (or nonadherence with guidelines) is associated with a worse prognosis. The study objective was to evaluate whether this was also the case in a large contemporary series of unselected patients with AF in real-world clinical practice. METHODS: All patients with AF or atrial flutter seen in our institution between 2000 and 2007 were identified in a database and followed up for mortality and stroke. Antithrombotic guideline adherence was assessed according to the 2006 American College of Cardiology/American Heart Association/European Society of Cardiology guidelines. RESULTS: We reviewed outcomes in 3,646 consecutive patients with AF or atrial flutter (aged 71 ± 14 years; mean CHADS(2) [congestive heart failure, hypertension, aged ≥ 75 years, diabetes mellitus, prior stroke or transient ischemic attack] score, 1.5 ± 1.1). Antithrombotic treatment was in agreement with the guidelines in 53% of patients, whereas 31% were classified as undertreated and 16% as overtreated. Among other parameters, nonpermanent AF and atrial flutter were independently associated with an increased risk of undertreatment. After a follow-up of 953 ± 767 days (median, 771 days; interquartile range, 1,286 days), guideline adherence was associated with a lower risk of adverse events (death from all causes or stroke) compared with undertreatment (relative risk, 0.47; 95% CI, 0.40-0.55; P < .0001). Overtreatment was associated with a lower risk of adverse events compared with the guideline-adherent population (relative risk, 0.40; 95% CI, 0.28-0.58; P < .0001). Factors independently associated with increased risk of mortality or stroke were antithrombotic undertreatment, older age, heart failure, renal failure, diabetes, male sex, and previous history of stroke. CONCLUSIONS: Guideline nonadherence and undertreatment with antithrombotic agents in unselected real-world patients with AF or atrial flutter are independently associated with a high risk of stroke and mortality.
Authors: Nicolae Done; Amanda M Roy; Yingzhe Yuan; Steven D Pizer; Adam J Rose; Julia C Prentice Journal: Health Serv Res Date: 2018-11-11 Impact factor: 3.402
Authors: Supriya Shore; Evan P Carey; Mintu P Turakhia; Cynthia A Jackevicius; Fran Cunningham; Louise Pilote; Steven M Bradley; Thomas M Maddox; Gary K Grunwald; Anna E Barón; John S Rumsfeld; Paul D Varosy; Preston M Schneider; Lucas N Marzec; P Michael Ho Journal: Am Heart J Date: 2014-04-05 Impact factor: 4.749
Authors: Karl Georg Haeusler; Andrea Gerth; Tobias Limbourg; Ulrich Tebbe; Michael Oeff; Karl Wegscheider; András Treszl; Ursula Ravens; Thomas Meinertz; Paulus Kirchhof; Günter Breithardt; Gerhard Steinbeck; Michael Nabauer Journal: BMC Neurol Date: 2015-08-05 Impact factor: 2.474
Authors: Derk L Arts; Stefan Visscher; Wim Opstelten; Joke C Korevaar; Ameen Abu-Hanna; Henk C P M van Weert Journal: PLoS One Date: 2013-07-05 Impact factor: 3.240